_:n4364123c1ef44a1aadbb15e813acd1b9xb5
<http://schema.org/transcript>
"ED: JOHNSON & JOHNSON HAS ASKED THE FDA TO AUTHORIZE BOOSTER SHOTS FOR ITS COVID-19 VACCINE. HERE TO ANSWER SOME QUESTIONS IS DR. TODD ELLERIN, CHIEF OF INFECTIOUS DISEASES AT SOUTH SHORE HEALTH. GREAT TO SEE YOU, D,R. AS ALWAYS, THANK YOU FOR JOINING US. MARIA: WE APPRECIATE YOU BEING HERE. AS YOU KNOW, J&J DISTRIBUTESHE T ONLY SINGLE-SHOT VACCINE AUTHORIZED IN THE UNITED STATES. SO, THIS NEW BOOSTER MORE LIKE A SECOND SHOT? WHAT CAN YOU TELL US ABOUTT? I DR. ELLEN:RI IT’S A LITTLE TRICKY. SOME OF IT IS SEMANTICS. THE BOOST IS THAT XSI MONTHS, THEY CAN PROBABLY CALL IT A SINGLE SHOT WITH THE BOOSTER. IF IT’S TWO MONTHS AFTER,T THA MIGHT BE CONSIDERED A SECOND SHOT. EIERTH WAY, WE KNOW THAT THE ADDITIONAL USED GETS YOU HIGHER IMMUNITY AND MORE PROTECTION AGAINST COVID. ED: WE ARE PUTTING A GRAPHIC ON THE SCREEN. THIS IS A BREAKDOWN OF HOW NYMA PEOPLE IN MASSACHUSETTS HAVE GOTTEN EITHER THE PFIZ,ER MODERNA OR J AND J VACCINE. J AND J IS THE SMALLEST GROUP BUT IT STILL IMPACTS MORE THAN 300,000 PEOPLE. THE QUESTION IS HOW DOES THEIR , PROTECTION LEVEL RIGHT NOW, WITHOUT THE BOTEOSR SHOT, COMPARE TO PEOPLE WHO GOT PFIZER OR MODERNA? ED: IT’S A GOOD -- DR. ELLERIN: IT’S A GOOD QUESTION. THEY LOOK AT 3700 U.S. ADULTS YESTERDAWHY O ARE ALL HOSPALITIZED. NONE OF THEM ARE IMMUNOCOMPROMISEITD  SHOWED INFERENCES. THOSE THAT RECEIVED MODERNA, THE EFFECTIVENESS WAS 93% AGAINST HOSPITALIZATION AND WITH PFIZER IT WAS $.88. WI TH THE J&J 71%. ANOTHER THING THAT’S INTERESTING IS THAT OVER TIME, AFTER ABTOU FOUR MONTHS THE EYES OR EFFICACY DROP, WHERE IS MODERNITY STATE HIGHER. SO, WE ARE SEEING SOME DIFFERENT -- DIFFERENCES. STATISTICIANS WILL SAY THAT THEY HAVEOT N BEEN DIRECTLY COMPARED AGAINST EACH OTHER, THESE ARE OBSERVATIONAL STUDIES THAT YOU HAVE TO TAKE WITH A BIT OF A GRAIN OF SALT. MAA:RI WE NEED TO TALK ABOUT THAT VERY RARE RISK OF BLOOD CLOTS FOR WOMEN YOUNGER THAN 50 AFTER GETTING THE J&J VACCINE. WHAT SHOULD THEY KNOW BEFORE GEINTTG A BOOSTER? DOES IT IMPACT MEN AS WELL? DR. ELLEN:RI REMEMBER, THERE IS A WARNING ABOUT THEOMEN W UNDER 50 AND INCREASED RISK OF CLOTS WI THETH VACCINE. YOU STILL HAVE TO REALIZE THAT THIS IS EXCEEDINGLRA,REY  OK? IT’S IMPORTANT TO KNOW, IF YOU AR E A WOMAN UNDER 50 AND YOU WANT TO THINK ABOUT ALTERNATIVE VACCINES, THAT’S WHEN IT’S TIME TO LET THE PERSON HAVE A MESSENR RNAGE VACCINE, IT’S REASONABLE AS A BOOSTER. BUT YOU WANT TO ALLOW THAT PERSON TO HAVE AN INDIVIDUAL DECISION. ED: WE ARE STILL WAITING FOR GUIDANCE FROM THE FDA AND CDC ABOUT MIXING AND MATCHING VACCINES. INKING YOU MIGHT WANT  GTOET MODERNA, WHAT DO YOU HOPE IS DECIDED? DR. ELLEN:RI THIS IS IMPORNTTA AND THE NATIONAL INSTITUTES OF HEALTH IS STUDYING THIS RIGHT NOW. WHAT WE DON’T KNOW IS IF PFIZER, BEFORE MODERNA, WITH THAT BE BETTER TNHA MODERNA BEFORE PFIZER? WH AATBOUT J&J FOLLOWED BY MODERNIT?Y THERE ARE A LOT OF DIFFERENT VARIABLES AND IT’S AN ADAPTIVE STUDY SO THE NIH IS LOOKING AT A LOT OF THESE AND WE WILL VEHA TO WAIT AND SEE WTHA HAPPENS AND ULTIMALYTE I THINK THAT MIXING AND MATCHING IS GOING TO ALLOW FOR A SK.IC MAA:RI I HAVE TO GO BACK, I INCLUDED MEN AND THAT IS WELL IN THE RARE COMPLICATIONS ONLY SEEMED TO APPLY TO WOMEN IN TERMS OF WHAT WE HAVE SEEN FOR TADA DR. ELLERIN: THAT’S RIGHT BUT IT’S RELATIVE, THE OVERALL RISK IS EXTREMYEL LOW. THE RISKS OF CLOTTING AND COVID ARE MUCH GREATER THEN THE RISKS OF HAVING A CTLO FROM ONE OF TH"
<https://www.wcvb.com/article/massachusetts-doctor-dr-todd-eller-in-johnson-johnson-covid-19-booster-shot/37874530>